# reload+after+2024-01-22 03:39:42.291287
address1§295 Rokeby Road
address2§Suite 1
city§Subiaco
state§WA
zip§6008
country§Australia
phone§61 8 6555 2950
fax§61 8 6166 0261
website§https://mgcpharma.com.au
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Roby Reuven Zomer', 'age': 43, 'title': 'Co-Founder, CEO, MD & Executive Director', 'yearBorn': 1980, 'fiscalYear': 2023, 'totalPay': 187025, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tom  Cairns', 'title': 'Chief Accounting Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Yifat  Steuer', 'title': 'Deputy CEO & COO', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Nicole Ann Godresse', 'title': 'Global Chief Sales Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Amir  Polak', 'title': 'Chief Pharmaceutical Development Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sabina  Suljakovic', 'title': 'Head of the Quality Assurance Department', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nadya  Lisovoder', 'title': 'Chief Medical Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sasha  Friedman', 'title': 'Deputy CEO', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Yair  Tal', 'title': 'Chief Information Security Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Clements', 'title': 'Chief Commercial Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.993
priceToSalesTrailing12Months§2.829265
currency§GBp
exchange§LSE
quoteType§EQUITY
shortName§MGC PHARMACEUTICALS LIMITED ORD
longName§MGC Pharmaceuticals Limited
firstTradeDateEpochUtc§1612857600
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§4327cf58-d950-39f5-a8d2-57da3181c7e2
recommendationKey§none
quickRatio§0.058
grossMargins§0.37976003
ebitdaMargins§0.0
trailingPegRatio§None
